证券代码：300584 证券简称：海辰药业 南京海辰药业股份有限公司投资者关系活动记录表 编号：2018-002 | --- | --- | --- | |----------------|-----------------------------------|----------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 □分析师会议 | | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 1 兴业证券 | | | 人员姓名 | 2 兴业证券 | | | | 3 中银基金 陈军 | | | | 4 中银基金 刘潇 | | | 时间 | 2018 年 5 月 8 | 14:00-16:00 | | 地点 | 南京海辰药业股份有限公司会议室 | | | 上市公司接待人 | | 董事长兼总经理 曹于平 先生 | | 员姓名 | | 副总经理、董事会秘书 严美强 先生 | | | | 财务总监 刘清 ...

证券代码：300584 证券简称：海辰药业 南京海辰药业股份有限公司投资者关系活动记录表 编号：2018-004 | --- | --- | --- | |--------------|----------------------------------|-----------------------------------| | | | | | 投资者关系活 | √ 特定对象调研 □分析师会议 | | | 动类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | □ 其他 （请文字说明其他活动内容） | | 参与单位名称 | 1 、国泰君安证券 | 孙明达 | | 及人员姓名 | 2 、中信证券权益投资部 刘瑞雯 | | | | 3 、兴业证券自营 储乐延 | | | | 4、诺安基金 | 刘红辉 | | | 5、光大资管 | 张宇初 | | | 6、中信保诚基金 王 岩 | | | | 7 、展博投资 张盛华 | | | | 8 、百年保险资管 | 陈 兴 | | | 9、 RPower Capital | 劳逸华 | | | 10 、经纬寰宇投 ...

证券代码：300584 证券简称：海辰药业 编号：2021-002 1 南京海辰药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活 | | √特定对象调研 □分析师会议 | | 动类别 | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | □其他 （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 金世富盈（北京）投 ...

Financial Performance - The company's revenue for Q3 2022 was ¥111,634,892.16, a decrease of 18.29% compared to the same period last year[5]. - Total operating revenue for Q3 2022 was ¥379,213,500.69, a decrease of 16.4% compared to ¥453,522,480.87 in Q3 2021[20]. - Operating profit for Q3 2022 was ¥23,657,656.42, a decline of 21% from ¥29,936,871.36 in Q3 2021[20]. - Net profit attributable to shareholders was ¥2,360,978.20, down 66.73% year-on-year[5]. - Net profit for the third quarter was ¥19.76 million, down 28.5% from ¥27.53 million year-over-year[21]. - Basic and diluted earnings per share were both ¥0.1674, compared to ¥0.2353 in the previous year, reflecting a decline of 29%[21]. Cash Flow - The company reported a net cash flow from operating activities of -¥53,606,799.17, a significant decline of 268.17%[5]. - Cash flow from operating activities showed a net outflow of approximately ¥53.61 million, contrasting with a net inflow of ¥31.88 million in the same quarter last year[22]. - The net cash flow from investment activities increased by 242.95% to ¥101,958,136.28, driven by equity transfer gains and investments in financial products[10]. - Cash inflow from investment activities was approximately ¥457.39 million, significantly higher than ¥40.15 million in the previous year[22]. - Cash flow from financing activities resulted in a net outflow of approximately ¥72.01 million, compared to a net inflow of ¥27.60 million in the previous year[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,236,939,727.03, a decrease of 5.00% from the end of the previous year[5]. - Total current assets reached ¥368,903,155.77, up 22.1% from ¥301,955,213.06[18]. - Total liabilities decreased to ¥298,363,396.37 from ¥353,530,387.82, a reduction of 15.6%[18]. - Non-current assets totaled ¥868,036,571.26, down 13.2% from ¥1,000,053,089.99[18]. Accounts and Inventory - Accounts receivable increased by 38.48% to ¥153,636,321.57 due to slower customer payment collection[9]. - Inventory rose to ¥65,911,272.79, an increase of 19.5% compared to ¥55,160,644.73[18]. - Prepayments rose by 147.55% to ¥16,680,139.96 as a result of unsettled prepayments[9]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,890, with the largest shareholder holding 42.08% of the shares[12]. - The total number of restricted shares at the beginning of the period was 55,954,749, with an increase of 6,024,456 restricted shares by the end of the period[14]. Other Financial Metrics - The basic earnings per share decreased by 66.67% to ¥0.0197[5]. - The weighted average return on equity was 0.25%, down 0.78% from the previous year[5]. - The company reported a total non-operating income of ¥30,782.10 for the reporting period[6]. - The company's minority shareholder equity dropped by 100% to ¥0, as a subsidiary's minority shareholders exited, converting their equity to capital reserves[10]. - The company reported a 129.39% increase in asset impairment losses to -¥2,316,534.59, due to increased provisions for inventory depreciation[10]. Market Conditions - Sales expenses fell by 30.14% to ¥186,390,916.67, primarily due to market promotion restrictions caused by the pandemic[10]. - Cash received from sales of goods and services totaled ¥359.67 million, down 25% from ¥478.99 million year-over-year[22]. Audit Status - The company has not undergone an audit for the third quarter report[24].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥267,578,608.53, a decrease of 15.56% compared to ¥316,902,875.42 in the same period last year[21]. - The net profit attributable to shareholders was ¥17,721,523.59, down 16.16% from ¥21,136,165.02 year-on-year[21]. - Basic earnings per share decreased to ¥0.1477, down 16.13% from ¥0.1761 in the same period last year[21]. - The total comprehensive income for the period was CNY 23,847,193.40, a decrease of 23.8% from CNY 31,300,333.12 in the previous year[158]. - The company reported a net profit of 568.5 million yuan, representing a profit margin of approximately 58.4%[176]. - The total revenue for the first half of 2022 was 974.0 million yuan, showing a significant increase compared to the previous period[176]. Cash Flow and Investments - The net cash flow from operating activities was negative at -¥34,649,138.87, a significant decline of 199.35% compared to ¥34,877,548.04 in the previous year[21]. - The company reported a significant increase in investment income, with a net cash flow from investing activities of ¥115.66 million, compared to a negative cash flow of ¥39.46 million in the previous year[56]. - The company experienced a significant increase in cash inflow from investment activities, totaling CNY 417,035,538.46, compared to CNY 30,062,166.66 in the previous year[159]. - The total cash inflow from investment activities was 416,968,574.86 RMB, significantly higher than 30,062,166.66 RMB in the first half of 2021[163]. - The company received 220,000,000.00 RMB in borrowings during the first half of 2022, compared to 125,000,000.00 RMB in the same period of 2021[164]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,252,498,364.79, a decrease of 3.80% from ¥1,302,008,303.05 at the end of the previous year[21]. - The total assets of Nanjing Haisun Pharmaceutical Co., Ltd. as of June 30, 2022, amounted to CNY 1,252,498,364.79, a decrease from CNY 1,302,008,303.05 at the beginning of the year[145]. - Total liabilities decreased to CNY 308,222,297.64 as of June 30, 2022, compared to CNY 340,434,699.12 at the beginning of the year, a decline of 9.4%[151]. Research and Development - Research and development investment decreased by 35.54% to ¥18.23 million from ¥28.28 million, indicating a reduction in R&D activities during the reporting period[56]. - The company has made significant progress in the consistency evaluation of generic drugs, with the injection of tigecycline's application for consistency evaluation approved during the reporting period[42]. - The company is actively improving its R&D capabilities to mitigate risks associated with new drug development[77]. - The company plans to continue its research and development efforts in new products and technologies to enhance its market position[171]. Market and Product Development - The company holds 73 drug approval numbers, with major products included in the national medical insurance catalog, focusing on innovative and high-quality products[31]. - The injection drug Torasemide, a new generation diuretic, faced sales impact due to market competition and price pressures from low-cost alternatives[32]. - The company has developed a leading position in the domestic market for tolvaptan and tigecycline, with tolvaptan being a leading brand in its segment[38]. - The company is focusing on expanding its market presence through refined promotion strategies for both finished and raw pharmaceutical products[37]. - The company is exploring market expansion opportunities in Southeast Asia, aiming for a 10% market share by the end of 2023[175]. Environmental and Social Responsibility - The company emphasizes social responsibility, focusing on the development of affordable medicines and actively participating in community welfare initiatives[101]. - The company prioritizes environmental protection and sustainable development, ensuring that waste is treated properly and emissions meet regulatory standards[103]. - The company has established a wastewater treatment system with a design capacity of 40 tons per hour, ensuring compliance with the GB8978-1996 Class III standard for wastewater discharge[92]. - The company has implemented a comprehensive air purification system to manage dust generated during production, ensuring no external emissions[92]. Governance and Compliance - The company has established a robust governance structure to protect the interests of shareholders, particularly minority shareholders, and maintains good credit with banks[102]. - There were no significant legal disputes or non-compliance issues reported during the period[112]. - The company has not engaged in any non-operational fund occupation by major shareholders or related parties[108]. - The financial report for the first half of 2022 was not audited[143]. Future Outlook and Strategy - The company plans to issue A-shares, but market demand and competition pose risks to the expected benefits of new capacity[79]. - The company has set a performance guidance for the next half of the year, targeting a revenue increase of 15%[176]. - There are plans for potential mergers and acquisitions to enhance product offerings and market presence[175].

Financial Performance - The company's revenue for Q1 2022 was ¥150,605,102.60, a decrease of 7.15% compared to ¥162,203,581.18 in the same period last year[4] - Net profit attributable to shareholders was ¥12,620,961.53, down 6.58% from ¥13,509,866.40 year-on-year[4] - Basic earnings per share decreased to ¥0.1052, down 6.57% from ¥0.1126 in the same period last year[4] - Total operating revenue for Q1 2022 was CNY 150,605,102.60, a decrease of 7.83% from CNY 162,203,581.18 in Q1 2021[23] - Net profit for Q1 2022 was CNY 12,448,499.59, a decline of 6.39% compared to CNY 13,297,482.78 in Q1 2021[24] Cash Flow - The net cash flow from operating activities was -¥40,136,476.98, a significant decline of 321.09% compared to ¥18,153,992.05 in the previous year[4] - Cash received from sales of goods and services in Q1 2022 was CNY 121,681,320.26, down from CNY 178,421,659.53 in Q1 2021[27] - The net cash flow from investment activities was 23,247,822.60 CNY, recovering from a negative cash flow of -7,659,685.62 CNY in the previous year[28] - The total cash outflow from operating activities was 174,462,859.63 CNY, compared to 160,649,033.98 CNY in the previous year, indicating higher operational costs[28] - The company paid 21,065,428.43 CNY in taxes, down from 27,214,092.77 CNY in the previous year, suggesting a potential decrease in taxable income[28] Assets and Liabilities - Total assets increased by 1.36% to ¥1,319,690,403.80 from ¥1,302,008,303.05 at the end of the previous year[7] - The company's total current assets at the end of the reporting period were 501.33 million yuan, compared to 301.96 million yuan at the beginning of the year[19] - Total liabilities as of the end of Q1 2022 were CNY 358,842,603.35, slightly up from CNY 353,530,387.82 in Q1 2021[21] - The company's total equity as of the end of Q1 2022 was CNY 960,847,800.45, an increase from CNY 948,477,915.23 in Q1 2021[21] Research and Development - The company's R&D expenses decreased by 37.61% to ¥4,789,264.33 from ¥7,676,524.25 year-on-year[9] - Research and development expenses for Q1 2022 were CNY 4,789,264.33, a decrease of 37.73% from CNY 7,676,524.25 in Q1 2021[24] Sales Performance - Sales of injectable Lantanol increased significantly, reaching 25.22 million yuan, a year-on-year increase of 34,617%[14] - The sales volume of injectable Lantanol reached 181,100 units, up 125,669% year-on-year[14] - Sales of Rivaroxaban tablets amounted to 14.86 million yuan, maintaining stable sales despite the impact of the Spring Festival and the pandemic[14] Investment Activities - The company’s cash flow from investing activities was ¥23,247,822.60, a significant improvement from -¥7,659,685.62 in the previous year[9] - Total cash inflow from investment activities was 246,432,426.11 CNY, a substantial increase from 30,062,166.66 CNY year-over-year[28] - The cash inflow from recovering investments was 246,412,538.11 CNY, a notable increase from 30,062,166.66 CNY in the previous year, highlighting improved investment recovery efforts[28] Borrowings and Equity - The company’s short-term borrowings decreased by 34.00% to ¥66,069,130.56 from ¥100,109,270.85[9] - Deferred income tax liabilities decreased to CNY 22,293,792.09 from CNY 41,466,021.50 in the previous year[21]

Financial Performance - The company's operating revenue for 2021 was ¥578,315,038.29, a decrease of 18.12% compared to ¥706,295,710.22 in 2020[19]. - Net profit attributable to shareholders was ¥285,878,182.25, an increase of 417.61% from ¥55,230,052.39 in 2020[19]. - The net profit after deducting non-recurring gains and losses was ¥24,051,742.89, down 54.66% from ¥53,042,549.07 in 2020[19]. - The total assets at the end of 2021 were ¥1,302,008,303.05, representing a 43.63% increase from ¥906,518,927.96 at the end of 2020[19]. - The weighted average return on equity was 35.18%, up 26.84 percentage points from 8.34% in 2020[19]. - The company reported a net cash flow from operating activities of ¥59,940,771.89, a decrease of 18.32% from ¥73,388,593.52 in 2020[19]. - The company received government subsidies amounting to ¥2,429,575.12 in 2021, down from ¥3,515,398.96 in 2020[24]. - The total sales amount from the top five customers was ¥67,337,192.84, accounting for 11.65% of the annual total sales[74]. - The total procurement amount from the top five suppliers was ¥16,200,667.32, representing 31.44% of the annual total procurement[75]. - The company reported a total procurement volume of 243,800 units for Rivaroxaban at a price of 72.31 RMB per 15mg*7 tablets in national procurement[52]. Dividend and Profit Distribution - The company reported a profit distribution plan based on a base of 120,000,000 shares, proposing a cash dividend of 2.50 RMB per 10 shares (including tax) and no bonus shares[5]. - The company distributed a cash dividend of RMB 1.25 per 10 shares, totaling RMB 15 million for the 2020 fiscal year[163]. - The company proposed a cash dividend of 2.50 CNY per 10 shares, totaling 30 million CNY for the year 2021, which represents 100% of the distributable profit[166]. - The company has no plans for stock bonuses or capital reserve transfers for the year 2021, with all undistributed profits carried forward to the next year[167]. - The independent directors have confirmed that the profit distribution plan aligns with the company's performance growth and protects the interests of all shareholders[166]. Research and Development - The company is focused on the development of generic drugs and aims to ensure quality and efficacy consistency with original drugs[13]. - The company is engaged in ongoing research and development to innovate new products and technologies in the pharmaceutical field[13]. - The company has established a strong presence in the pharmaceutical market, with a focus on expanding its product offerings and market reach[13]. - The company is actively enhancing its R&D capabilities, focusing on both independent and collaborative research to ensure a continuous pipeline of new products[46]. - The company has submitted three invention patent applications, strengthening its intellectual property protection and enhancing core competitiveness[51]. - The company is advancing multiple R&D projects, including the completion of the synthesis process for Dabigatran and the establishment of corresponding quality standards[78]. - The company has ongoing applications for various products, including Apixaban and Montelukast, which are currently under review, indicating a robust pipeline[49]. - The company plans to enhance research and development efficiency and focus on innovation management in 2022[110]. - The company has established a dedicated team for innovative drug research to foster new drug development[110]. Market and Product Development - The company has 73 approved drug products, with major products included in the 2021 National Medical Insurance Directory[36]. - The company’s main products include Torasemide injection, Tigecycline injection, and Labetalol hydrochloride injection, which are positioned in various therapeutic areas[36]. - The company’s Torasemide injection is a new generation diuretic with a strong and lasting effect, but faced market challenges due to low-priced competitors[36]. - The company has completed the registration for the seventh batch of national drug procurement for Tigecycline injection, aiming to enhance market coverage[37]. - The company is focusing on improving product quality standards through consistency evaluation applications for several injectable products, which are expected to enhance competitiveness[49]. - The company is actively expanding its market presence for injectable Labetalol and Rivaroxaban tablets, which are expected to be major growth points in 2022[113]. - The company aims to optimize its product structure with the inclusion of new products in the medical insurance directory, which is expected to drive growth[109]. Operational Efficiency and Cost Management - The company is committed to reducing drug procurement prices through volume-based procurement strategies, which could alleviate medical expenses[13]. - The company has established a complete quality management system and maintains stable relationships with key suppliers, ensuring smooth procurement channels[42]. - The company's operating costs decreased due to a decline in annual revenue, with fixed costs increasing as a percentage of total costs[73]. - The company reported a 60.03% decrease in raw material costs, which accounted for 35.09% of total operating costs in 2021[73]. - The company has established a marketing network covering over 1,000 distributors and approximately 3,000 hospitals nationwide[65]. - The company is expanding its online and offline sales channels to enhance its marketing strategy[65]. Governance and Compliance - The company has established a comprehensive governance structure, including a board of directors and supervisory board, ensuring effective checks and balances[129]. - The company maintains complete independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring a fully independent business model[130]. - The company has a structured governance framework with clear responsibilities among the shareholders' meeting, board of directors, and supervisory board[171]. - The company has a clear governance structure that includes independent oversight by non-executive directors[146]. - The company has a performance evaluation system to assess the effectiveness of its directors and senior management annually[147]. - The company has maintained compliance with regulatory requirements regarding the remuneration of its board members and executives[148]. Environmental Responsibility - The company has implemented a waste gas treatment process with a 90% efficiency rate for organized waste gas, ensuring compliance with emission standards[181]. - The company has constructed a 100 tons per day wastewater treatment facility, which further discharges to the local wastewater treatment plant for additional purification[183]. - The company has established a solid hazardous waste storage facility and follows strict regulations for the storage and transfer of hazardous waste[182]. - The company has conducted environmental monitoring for air and water quality throughout 2021, with all results meeting regulatory standards[185]. - The company actively participates in environmental protection and sustainable development, ensuring compliance with environmental regulations and investing in clean production facilities[188]. Employee and Training Initiatives - The total number of employees at the end of the reporting period was 563, with 186 in production, 105 in sales, and 155 in technical roles[160]. - The company conducted 231 training sessions during the reporting period, totaling 1,517 hours, to enhance employee skills and efficiency[162]. - The company has a competitive compensation policy that includes basic salary, sales bonuses, and various employee benefits[161]. - The company aims to enhance employee capabilities through various training programs, contributing to its competitive edge in the pharmaceutical industry[171]. Risks and Challenges - The company emphasizes the importance of understanding risks such as industry policy changes, drug price reduction risks, and R&D risks, which could impact future performance[5]. - The company is facing risks from industry policy changes, including price reductions due to centralized procurement, which may impact profitability[117][118]. - The company reported a significant impact from natural disasters and public health emergencies on its operations, which could affect normal production and business activities[123].

南京海辰药业股份有限公司 2021 年第三季度报告 证券代码：300584 证券简称：海辰药业 公告编号：2021-047 南京海辰药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 136,619,605.45 | -20.62% | 453,522,480.87 | -17.2 ...

Industry Impact and Risks - The company reported a significant impact from industry policy changes, including drug approval and procurement reforms, which pose risks to future operations [5]. - The company is facing significant risks due to changes in industry policies, which could impact drug approval, quality supervision, and procurement processes [88]. Research and Development - The company is focusing on improving R&D capabilities and has initiated consistency evaluations for its main products to mitigate risks associated with new drug development [6]. - The company aims to enhance its academic brand building for its products, particularly those that meet medical insurance negotiation requirements [33]. - The company is actively pursuing new product development and strategic partnerships to expand its R&D pipeline [6]. - The company is enhancing its R&D capabilities to mitigate risks associated with long development cycles and potential project failures, focusing on strategic new product development [89]. - The company has established a comprehensive R&D system, recognized as a provincial technology center, and has undertaken over 20 national and provincial-level technology projects [55]. - The company is transitioning from generic drugs to innovative drugs, with a focus on clinical development and registration of new candidates [44]. - The company has initiated consistency evaluations for its generic injectable drugs, which are crucial for maintaining market access [91]. Financial Performance - The company's operating revenue for the reporting period was ¥316,902,875.42, a decrease of 15.68% compared to ¥375,842,580.80 in the same period last year [24]. - The net profit attributable to shareholders was ¥21,136,165.02, down 42.07% from ¥36,485,998.26 year-on-year [24]. - The net profit after deducting non-recurring gains and losses was ¥20,507,510.71, a decrease of 41.80% compared to ¥35,234,588.74 in the previous year [24]. - The net cash flow from operating activities increased significantly by 245.75%, reaching ¥34,877,548.04 compared to ¥10,087,405.58 in the same period last year [24]. - The total assets at the end of the reporting period were ¥901,849,900.08, a slight decrease of 0.52% from ¥906,518,927.96 at the end of the previous year [24]. - The net assets attributable to shareholders increased by 0.88%, amounting to ¥685,752,270.03 compared to ¥679,774,827.09 at the end of the previous year [24]. Environmental Compliance - The company plans to enhance its environmental protection measures in response to increasing regulatory requirements, which may affect operational costs [7]. - The company emphasizes the importance of compliance with environmental standards to avoid penalties and ensure sustainable operations [7]. - Nanjing Haichen Pharmaceutical reported a total wastewater treatment capacity of 40 tons per hour, ensuring compliance with the GB8978-1996 Class III standard [101]. - The company has not exceeded the wastewater discharge limits, with all monitoring results meeting regulatory requirements [102]. - The company has implemented a comprehensive wastewater treatment system, ensuring no harmful emissions during production processes [102]. - The company has completed environmental protection facilities construction, with operations expected to start in October 2021 [104]. Strategic Partnerships and Acquisitions - The company has established a merger fund to acquire 90% of the Italian NMS Group, which specializes in innovative drug development, although operations were temporarily affected by the pandemic [6]. - NMS Group, acquired by the company, has made significant progress in product development, including the approval of Entrectinib and Encorafenib, contributing to improved financial metrics [52]. - The company has established a stable cooperation relationship with key suppliers, ensuring smooth procurement channels for raw materials [36]. Shareholder and Governance Matters - No cash dividends or stock bonuses will be distributed to shareholders for the reporting period [8]. - The company has a governance structure in place to manage its growing number of subsidiaries and joint ventures effectively [90]. - The controlling shareholders of Haicheng Pharmaceutical, Cao Yuping and Jiang Xiaoqun, committed to not transferring or entrusting the management of their shares for 36 months post-IPO [116]. - The company is committed to long-term shareholding and will adhere to regulations regarding share reduction [117]. - The company has made commitments to avoid related party transactions and ensure no fund occupation by controlling shareholders [120]. Operational Efficiency and Cost Management - The company aims to enhance its operational efficiency and reduce costs to enhance profitability in the upcoming quarters [192]. - The company is focusing on improving its operational efficiency and reducing costs to enhance profitability in the upcoming quarters [192]. - The company has effectively managed its investment projects to align with the planned progress for R&D and facility upgrades [81]. Market Expansion and Product Development - The company plans to focus on expanding the market for its injectable tigecycline, which is recognized as a "super antibiotic" and has significant growth potential [32]. - The company aims to accelerate product structure transformation and increase the promotion of key products to address the urgent need for development [37]. - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth [191]. Social Responsibility and Community Engagement - The company emphasizes social responsibility, focusing on the protection of shareholder interests and maintaining a robust governance structure [110]. - The company actively participates in social welfare, donating RMB 1.25 million worth of medicines to the Red Cross and supporting local educational initiatives [112].

南京海辰药业股份有限公司 2021 年第一季度报告全文 南京海辰药业股份有限公司 2021 年第一季度报告 2021-023 2021 年 04 月 1 南京海辰药业股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曹于平、主管会计工作负责人刘清华及会计机构负责人(会计主 管人员)吴国锋声明：保证季度报告中财务报表的真实、准确、完整。 2 南京海辰药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 162,203,581.18 | 166,174,066.04 | -2.39% | | 归属于上市公司股东的净利润（元） | 13,509,866.40 ...